Free Trial
NASDAQ:VNDA

Vanda Pharmaceuticals Q1 2025 Earnings Report

Vanda Pharmaceuticals logo
$4.57 +0.13 (+2.93%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$4.47 -0.10 (-2.10%)
As of 05/2/2025 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vanda Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
$0.05
Beat/Miss
N/A
One Year Ago EPS
N/A

Vanda Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$45.13 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vanda Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Vanda Pharmaceuticals Earnings Headlines

URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
Vanda says FDA ‘unlawfully’ delaying hearing
See More Vanda Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vanda Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vanda Pharmaceuticals and other key companies, straight to your email.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals (NASDAQ:VNDA), a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

View Vanda Pharmaceuticals Profile

More Earnings Resources from MarketBeat